Upcoming Login Downtime

We're updating the Biocentury.com platform login experience to make access more secure and reliable. As part of this update, logins will be temporarily unavailable on Sunday, March 16, from 4:00AM to 4:00PM GMT. We recognize the inconvenience and appreciate your understanding. Please check back after the maintenance period.

For updates, questions, or issues, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jan 20, 2022
Product Development

Moving beyond a 45-year-old antiviral for herpes

Improved antivirals, antibodies, vaccines and possible cures enter the horizon
BioCentury | Sep 29, 2017
Clinical News

Genocea discontinues HSV-2 candidate GEN-003

BioCentury | Oct 10, 2016
Clinical News

GEN-003: Phase IIb data

BioCentury | Apr 4, 2016
Clinical News

GEN-003: Additional Phase II data

BioCentury | Apr 1, 2016
Clinical News

Genocea gains on 12-month HSV data

BioCentury | Feb 8, 2016
Clinical News

GEN-003: Phase IIb started

BioCentury | Oct 12, 2015
Clinical News

GEN-003: Additional Phase II data

BioCentury | Oct 8, 2015
Clinical News

Genocea rises on six-month HSV-2 data

BioCentury | Jul 31, 2015
Financial News

Genocea raises $50.1M in follow-on

BioCentury | May 25, 2015
Clinical News

GEN-003: Phase II data

Items per page:
1 - 10 of 32